Merus (MRUS) to Release Quarterly Earnings on Wednesday

Merus (NASDAQ:MRUS - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($1.17) per share and revenue of $7.82 million for the quarter.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. On average, analysts expect Merus to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Merus Stock Down 3.4 %

NASDAQ MRUS traded down $1.45 during trading hours on Friday, hitting $41.32. The company had a trading volume of 556,197 shares, compared to its average volume of 720,469. The firm has a market cap of $2.86 billion, a P/E ratio of -10.46 and a beta of 0.94. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.61. The business has a fifty day simple moving average of $43.58 and a 200-day simple moving average of $44.23.

Analyst Ratings Changes

Several equities research analysts have commented on MRUS shares. Piper Sandler began coverage on shares of Merus in a research note on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price target on the stock. William Blair reaffirmed an "outperform" rating on shares of Merus in a research note on Monday, April 28th. HC Wainwright reiterated a "buy" rating and set a $85.00 price objective on shares of Merus in a research note on Monday, March 3rd. Bank of America cut their target price on Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $83.00 price objective on shares of Merus in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Merus presently has a consensus rating of "Buy" and an average target price of $85.15.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.